神经分泌生物科学 NBIX 深 沪
已收盘 02-06 16:00:00 美东时间
141.20
+3.270
+2.37%
华盛通- 最 高142.145
- 今 开138.75
- 成交量 115.40万股
- 最 低 138.27
- 昨 收 137.93
- 总市值 140.78亿
- 52周最高 160.18
- 市盈率 静 42.90
- 换手率 1.16%
- 52周最低 84.23
- 委 比 77.72%
- 总股本 9970.57万
- 历史最高 160.18
- 量 比 1.11
- 振 幅 2.81%
- 历史最低 5.42
- 每 手 1
- 风险率 14.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Neurocrine BiosciencesInitiates Phase 2 Clinical Study Evaluating NBI-1065890
This Phase 2, randomized, double-blind, placebo-controlled study will enroll approximately 100 adult subjects with TD and will assess the efficacy, safety, and tolerability of NBI-1065890 compared with placebo. The
01-26 21:38
Neurocrine Biosciences Launches Phase 2 Trial of New VMAT2 Inhibitor for Tardive Dyskinesia
Neurocrine Biosciences Launches Phase 2 Trial of New VMAT2 Inhibitor for Tardive Dyskinesia Neurocrine Biosciences Inc. has announced the initiation of a Phase 2 clinical study evaluating its investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890 is a next-generatio
01-26 21:31
美股大行评级 | 英特尔绩后获多家大行上调目标价；理想汽车、Mobileye、Meta、微软、甲骨文等遭下调目标价
今日重点评级关注：RBC Capital：维持Compass Pathways"跑赢大市"评级，目标价从16美元升至21美元；RBC Capital：维持GH Research"跑赢大市"评级，目标价从33美元升至40美元
01-26 14:32
What Analysts Are Saying About Neurocrine Biosciences Stock
Across the recent three months, 18 analysts have shared their insights on Neuro...
01-24 04:00
UBS Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $178
UBS analyst Ashwani Verma maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and lowers the price target from $188 to $178.
01-24 03:35
Neurocrine Biosciences Data Shows INGREZZA Delivers Nearly Double VMAT2 Occupancy vs. AUSTEDO XR
INGREZZA showed a nearly two-fold higher VMAT2 occupancy, consistent with greater potency when compared to AUSTEDO XR (deutetrabenazine) after a single dose of each treatmentVMAT2 occupancy is a key measurement thought
01-15 21:40
美股大行评级 | Medline获14家大行首予评级，最高目标价52美元；富国银行上调GOOGL目标价从268美元升至350美元
今日重点评级关注：HC Wainwright & Co.：维持Enlivex Therapeutics"买入"评级，目标价从7美元升至13美元；BTIG：维持Oruka Therapeutics"买入"评级，目标价从63美元升至73美元
01-13 10:18
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
Morgan Stanley Downgrades Neurocrine Biosciences to Equal-Weight, Raises Price Target to $175
Morgan Stanley analyst Jeffrey Hung downgrades Neurocrine Biosciences (NASDAQ:NBIX) from Overweight to Equal-Weight and raises the price target from $173 to $175.
01-08 20:16
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
The most oversold stocks in the health care sector presents an opportunity to b...
01-06 20:29
